Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 205

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2012', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma) .
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Bile Duct Cancer (Cholangiocarcinoma) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Products under Development, Key Players in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Bile Duct Cancer (Cholangiocarcinoma) Pipeline Overview, Bile Duct Cancer (Cholangiocarcinoma) Pipeline, Bile Duct Cancer (Cholangiocarcinoma) Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bile Duct Cancer (Cholangiocarcinoma) Overview
Therapeutics Development
An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Companies
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Products under Development by Companies
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development
AstraZeneca PLC
Novartis AG
Pfizer Inc.
Karo Bio
Marshall Edwards, Inc.
Provecs Medical GmbH
Mebiopharm Co., Ltd.
Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Immunalon - Drug Profile
ARRY-162 - Drug Profile
Triphendiol - Drug Profile
OTS102 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Chloroquine - Drug Profile
Tarceva - Drug Profile
Oxaliplatin + Capecitabine + Sorafenib - Drug Profile
Erlotinib + Gemox - Drug Profile
Irinotecan + Oxaliplatin - Drug Profile
Capecitabine + Epirubicin + Carboplatin - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
Stakel Mediated VTP Therapy - Drug Profile
Gemcitabine - Drug Profile
BAY 43-9006 - Drug Profile
Panitumumab + Gemcitabine + Oxaliplatin - Drug Profile
mFOLFOX6 + Bevacizumab - Drug Profile
Sunitinib - Drug Profile
Capecitabine - Drug Profile
AZD6244 - Drug Profile
Foscan - Drug Profile
Gemcitabine + Capecitabine - Drug Profile
Erlotinib + Gemcitabine + Oxaliplatin - Drug Profile
Carcinoembryonic Antigen RNA-Pulsed DC Cancer Vaccine - Drug Profile
Bosutinib + Capecitabine - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Davanat + 5-Fluorouracil - Drug Profile
Dolastatin 10 - Drug Profile
Capecitabine + Gemcitabine + Radiation Therapy - Drug Profile
Herceptin - Drug Profile
Gemcitabine + Capecitabine - Drug Profile
Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile
Zactima + Gemzar - Drug Profile
Tumor Infiltrating Lymphocytes + Cyclophosphamide + Fludarabine + Aldesleukin - Drug Profile
Gemcitabine + Cisplatin + Sorafenib - Drug Profile
Gemcitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin + S-1 - Drug Profile
Gemcitabine - Drug Profile
Gemcitabine + Sorafenib - Drug Profile
S-1 + Photodynamic Therapy - Drug Profile
S-1 + Cisplatin - Drug Profile
Gemcitabine + Irinotecan + Panitumumab - Drug Profile
Gemcitabine - Drug Profile
Gemzar + Taxotere - Drug Profile
Eloxatin + Xeloda - Drug Profile
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile
S-1 + Gemcitabine - Drug Profile
Cancer Specific Antigen-Derived Peptide Vaccine + Gemcitabine - Drug Profile
TS-1 + Gemcitabine - Drug Profile
Capecitabine + Oxaliplatin - Drug Profile
RAD001 - Drug Profile
Gemcitabine + Oxaliplatin + Capecitabine - Drug Profile
GEMOX - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
HLA-A 2402 Restricted A2691N Peptide + D0006 Peptide + F2861 Peptide + Montanide ISA-51 - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
S-1 - Drug Profile
TS-1 - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
Gemcitabine - Drug Profile
Irinotecan + Gemcitabine - Drug Profile
Gemcitabine + TS-1 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + S-1 - Drug Profile
Cisplatin - Drug Profile
Epirubicin + Carboplatin + Capecitabine - Drug Profile
mFOLFOX - Drug Profile
Gemox - Drug Profile
UFT + Leucovorin - Drug Profile
Gemcitabine + S-1 - Drug Profile
Gemcitabine - Drug Profile
Glivec + 5-Fluorouracil + Leucovorin - Drug Profile
Fludarabine + Cyclophosphamide + CD8+ Enriched TIL + Aldesleukin - Drug Profile
Gecitabine + Cisplatin + S-1 - Drug Profile
SOX - Drug Profile
Gemcitabine - Drug Profile
Gemcitabine + Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile
Gemcitabine + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile
5-Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Gemcitabine + TS-1 - Drug Profile
Gemcitabine + Capecitabine - Drug Profile
Gemcitabine + Oxaliplatin - Drug Profile
Porfimer - Drug Profile
Gemcitabine - Drug Profile
Cetuximab + Gemcitabine + Oxaliplatin - Drug Profile
Modified FOLFOX6 + AZD2171 - Drug Profile
Docetaxel + Oxaliplatin - Drug Profile
Cisplatin + Gemcitabine + Selumetinib - Drug Profile
KB9520 - Drug Profile
MBP-Y005 - Drug Profile
S-1 + Oxaliplatin - Drug Profile
Gemcitabine - Drug Profile
S-1 - Drug Profile
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile
GEMOX + Cetuximab - Drug Profile
Cisplatin + Gemcitabine + Panitumumab - Drug Profile
Gemcitabine + Cisplatin + S-1 - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Cisplatin + Carboplatin + Capecitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile
Gemox 85 - Drug Profile
Oxaliplatin + Gemcitabine + Radiation Therapy - Drug Profile
WT1 Peptide Vaccination + Gemcitabine + Cisplatin - Drug Profile
Gemcitabine + Cisplatin + S-1 - Drug Profile
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Drug Profile Updates
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Discontinued Products
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Dormant Products
Bile Duct Cancer (Cholangiocarcinoma) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2012
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
AstraZeneca PLC, H1 2012
Novartis AG, H1 2012
Pfizer Inc., H1 2012
Karo Bio, H1 2012
Marshall Edwards, Inc., H1 2012
Provecs Medical GmbH, H1 2012
Mebiopharm Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Drug Profile Updates
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Discontinued Products
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..1)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..2)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..3)

List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2012
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Bladder Cancer - Pipeline Review, H2 2012
• Adenocarcinoma - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Chemotherapy Effects – Pipeline Review, H1 2013
• Brain Cancer - Pipeline Review, H2 2012
• Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012
• Acne And Related Disorders - Pipeline Review, H1 2013
• Ocular Inflammation - Pipeline Review, H1 2013
• Cystic Fibrosis - Pipeline Review, H1 2013